Venture Medical

Are you interested in having your compelling wound cases highlighted as a poster or in a publication? Getting involved now could have a significant impact on the availability of CAMPs products in the near future. We have strong evidence to suggest that CMS will prioritize clinical data above all else when making product-based coverage and payment determinations. We are asking for your help. By contributing to the clinical evidence we already have, you can help ensure that wound care practices remain viable and that patients continue to have access to effective treatments. If you have treated a few, several, or many patients with Vendaje or AmnioWrap2, we can assist you in constructing a case study, case series, or even a retrospective study. There are several upcoming wound care conferences with opportunities to submit abstracts, and we are always looking for more real-world evidence! Poster abstract deadlines approaching: November 15th:?Boswick Symposium We realize this deadline is fast approaching; however, there are many more opportunities to present throughout 2025, and we encourage you to get a head start on your submissions. We have resources available to help you submit your abstract, along with peers ready to share their knowledge and best practices. If you are interested, please fill out this brief form, and a member of our team will reach out:?https://lnkd.in/d3UM5VrH

A proposed change in Medicare coverage would severely impact life-saving care for more than 600,000 patients many of whom have diabetes and suffer from painful wounds that won’t heal. Help us and the Diabetic Wound Awareness PAC to continue providing high quality care to patients experiencing diabetes related wounds by signing this petition. https://lnkd.in/g3kF9D9e

Congrats to BioStem Technologies and ProgenaCare Global!

Please help us welcome two new members to our team, Matt Goebel and Brian Nye! A little about our new Area Sales Directors: Matt Goebel, MBA brings over 25 years of experience in the medical industry to his professional endeavors. Most recently, he served as an Area Vice President at Nihon Kohden, where he led a dedicated team of ten account executives. In August, he decided to further enhance his skills and knowledge by returning to school to pursue an MBA. This experience has not only broadened his understanding of business principles but also reignited his passion for strategic thinking and innovation in the medical field. BRIAN NYE began his career with Rh?ne Poulenc Rorer as a pharma sales representative, then made the transition to Takeda Pharmaceuticals in 1999.?He spent 21 years there, with 18 of those in a commercial leadership capacity at the local, regional, and national levels.?Most recently, he served as VP of Commercial Development/Strategic Accounts/Sales Operations and VP of Sales in the preclinical and clinical space(s).?As a leader he loves getting ‘in the trenches’ with customers, but considers coaching, mentoring, and developing people to achieve company and their personal goals the most important aspect of his role.

Venture OneView: A complete and comprehensive software solution to help your wound care practice manage the entire revenue cycle process. Want to learn more? Schedule a demo with one of our Relationship Managers! https://lnkd.in/grxxjj6H

Rest assured that Venture Medical and our partners are working to ensure that patients with chronic wounds of all types will continue to have access to the most effective products on the market. We plan on sharing more information on our efforts in the coming days. If you're interested in learning about actions the Alliance is taking, be sure to join in on this conference call happening this evening.

More upcoming opportunities to have your compelling wound cases highlighted as a poster or publication! Getting involved now could have a significant impact on the availability of CAMPs products in the near future. We have strong evidence to suggest that CMS will prioritize clinical data above all else when making product-based coverage and payment determinations. We are asking for your help. By contributing to the clinical evidence we already have, you can help ensure that wound care practices remain viable and that patients continue to have access to effective treatments. If you have treated a few, several, or many patients with Vendaje or AmnioWrap2, we can assist you in constructing a case study, case series, or even a retrospective study. There are several upcoming wound care conferences with opportunities to submit abstracts, and we are always looking for more real-world evidence! Poster abstract deadlines approaching: January 3rd:?SAWC Spring 2025 January 30th: CAMPS There will be even more opportunities to present throughout 2025, and we encourage you to get a head start on your submissions. We have resources available to help you submit your abstract, along with peers ready to share their knowledge and best practices. If you are interested, please fill out this brief form, and a member of our team will reach out: https://lnkd.in/d3UM5VrH

Today, we get to celebrate not one but TWO rockstars in our office! Let’s hear it for John and Blake?– each a powerhouse in their own right. To John: The Ringleader of this Circus, bbq aficionado, and all-around amazing boss who can turn any challenge into a win. May your day be filled with new opportunities, a meadow full of bull elk, and maybe some well-deserved downtime! To Blake: Sales guru, team cheerleader, and legendary for his pen and paper loyalty. Here’s to a year of new milestones, trips to Missoula, and a LinkedIn feed full of well-wishers! Happy Birthday to both of you!?

At Venture Medical, we believe Cold Plasma is the future of wound care, and we’re excited to see this new document from the European Wound Management Association spotlight this innovative technology. We hope the United States will soon follow Europe’s lead in embracing this powerful modality for wound treatment. https://lnkd.in/g-e5QNm5

We are pleased to announce the upcoming publication in Journal of Wound Care (JWC) of a new paper examining the effects of ProgenaMatrix Human Keratin Matrix on the healing of venous leg ulcers (VLUs). The paper reports on two groups of complex VLUs, one group with very large VLUs (mean wound area 333 cm2), the other group of VLUs < 35 cm2 in area with a mean area of 17.55 cm2. Both groups reduced dramatically in size upon addition of ProgenaMatrix (HKM) to the treatment regimen. Very large VLUs showed a 50% size reduction with four applications of HKM or less. Small to medium sized VLUs reduced by 50% in size within the first three weeks of HKM application, and 88.9% of wounds in this group healed with an average of 4.5 applications. These results demonstrate the clinical benefits of ProgenaMatix across a wide range of wound sizes, including for very large VLUs which have so far not been widely studied. Congrats to Dr. George Koullias MD and Dr. Allison Ramey-Ward on this important contribution to the literature. Link in comments. #WoundHealing #Keratin #VLU #VenousLegUlcer